Maria J. Pajares

Maria J. Pajares

Auto-generated profile, based on publicly available information

Maria J. Pajares

Program in Solid Tumors, Center for Applied Medical Research, Pamplona, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
DADaniel Ajona
Daniel Ajona
CZCarolina Zandueta
Carolina Zandueta
LCLeticia Corrales
Leticia Corrales
HMHaritz Moreno
Haritz Moreno
MPMaría J. Pajares
María J. Pajares
FLFernando Lecanda
Fernando Lecanda
Rationale: C5aR1 (CD88), a receptor for complement anaphylatoxin C5a, is a potent immune mediator. Its impact on malignant growth and dissemination of non–small cell lung cancer cells is poorly understood. Objectives: To investigate the contribution of the C5a/C5aR1 axis to the malignant phenotype of non–small cell lung cancer cells, particularly in skeletal colonization, a preferential lung metastasis site. Methods: Association between C5aR1 expression and clinical outcome was assessed in silico and validated by immunohistochemistry. Functional significance was evaluated by lentiviral gene silencing and ligand l-aptamer inhibition in in vivo models of lung cancer bone metastasis. In vitro functional assays for signaling, migration, invasion, metalloprotease activity, and osteoclastogenesis were also performed. Measurements and Main Results: High levels of C5aR1 in human lung tumors were significantly associated with shorter recurrence-free survival, overall survival, and bone metastasis. Silencing of C5aR1 in lung cancer cells led to a substantial reduction in skeletal metastatic burden and osteolysis in in vivo models. Furthermore, metalloproteolytic, migratory, and invasive tumor cell activities were modulated in vitro by C5aR1 stimulation or gene silencing. l-Aptamer blockade or C5aR1 silencing significantly reduced the osseous metastatic activity of lung cancer cells in vivo. This effect was associated with decreased osteoclastogenic activity in vitro and was rescued by the exogenous addition of the chemokine CXCL16. Conclusions: Disruption of C5aR1 signaling in lung cancer cells abrogates their tumor-associated osteoclastogenic activity, impairing osseous colonization. This study unveils the role played by the C5a/C5aR1 axis in lung cancer dissemination and supports its potential use as a novel therapeutic target.

27 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IGIvana Grbesa
Ivana Grbesa
MPMaría J Pajares
María J Pajares
EMElena Martínez-Terroba
Elena Martínez-Terroba
JAJackeline Agorreta
Jackeline Agorreta
AMAna-Matea Mikecin
Ana-Matea Mikecin
Luis M MontuengaLuis M Montuenga
Luis M Montuenga
Sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) are NAD+-dependent protein deacetylases involved in the regulation of key cancer-associated genes. In this study we evaluated the relevance of these deacetylases in lung cancer biology. Protein levels of SIRT1 and SIRT2 were determined in non-small cell lung cancer (NSCLC) cell lines and primary tumors from 105 patients. Changes in proliferation were assessed after SIRT1 and SIRT2 downregulation in lung cancer cell lines using siRNA-mediated technology or tenovin-1, a SIRT1 and SIRT2 inhibitor. High SIRT1 and SIRT2 protein levels were found in NSCLC cell lines compared with non-tumor lung epithelial cells. The expression of SIRT1 and SIRT2 proteins was also significantly higher in lung primary tumors than in normal tissue (P<0.001 for both sirtuins). Stronger nuclear SIRT1 staining was observed in adenocarcinomas than in squamous cell carcinomas (P=0.033). Interestingly, in NSCLC patients, high SIRT1 and SIRT2 expression levels were associated with shorter recurrence-free survival (P=0.04 and P=0.007, respectively). Moreover, the combination of high SIRT1 and SIRT2 expression was an independent prognostic factor for shorter recurrence-free survival (P=0.002) and overall survival (P=0.022). In vitro studies showed that SIRT1 and/or SIRT2 downregulation significantly decreased proliferation of NSCLC. Our results support the hypothesis that SIRT1 and SIRT2 have a protumorigenic role in lung cancer, promoting cell proliferation. Moreover, the expression of these proteins is associated with poor prognosis in NSCLC patients and may help to identify those NSCLC patients with high risk of recurrence that could benefit from adjuvant therapy after resection.

1 October 2019 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
IIIrati Garmendia Iturbe
Irati Garmendia Iturbe
MPMaría J. Pajares
María J. Pajares
FHFrancisco Hermida-Prado
Francisco Hermida-Prado
DADaniel Ajona
Daniel Ajona
CBCristina Bértolo
Cristina Bértolo
JAJackeline Agorreta
Jackeline Agorreta
Rationale: The characterization of new genetic alterations is essential to assign effective personalized therapies in non–small cell lung cancer (NSCLC). Furthermore, finding stratification biomarkers is essential for successful personalized therapies. Molecular alterations of YES1, a member of the SRC (proto-oncogene tyrosine-protein kinase Src) family kinases (SFKs), can be found in a significant subset of patients with lung cancer. Objectives: To evaluate YES1 (v-YES-1 Yamaguchi sarcoma viral oncogene homolog 1) genetic alteration as a therapeutic target and predictive biomarker of response to dasatinib in NSCLC. Methods: Functional significance was evaluated by in vivo models of NSCLC and metastasis and patient-derived xenografts. The efficacy of pharmacological and genetic (CRISPR [clustered regularly interspaced short palindromic repeats]/Cas9 [CRISPR-associated protein 9]) YES1 abrogation was also evaluated. In vitro functional assays for signaling, survival, and invasion were also performed. The association between YES1 alterations and prognosis was evaluated in clinical samples. Measurements and Main Results: We demonstrated that YES1 is essential for NSCLC carcinogenesis. Furthermore, YES1 overexpression induced metastatic spread in preclinical in vivo models. YES1 genetic depletion by CRISPR/Cas9 technology significantly reduced tumor growth and metastasis. YES1 effects were mainly driven by mTOR (mammalian target of rapamycin) signaling. Interestingly, cell lines and patient-derived xenograft models with YES1 gene amplifications presented a high sensitivity to dasatinib, an SFK inhibitor, pointing out YES1 status as a stratification biomarker for dasatinib response. Moreover, high YES1 protein expression was an independent predictor for poor prognosis in patients with lung cancer. Conclusions: YES1 is a promising therapeutic target in lung cancer. Our results provide support for the clinical evaluation of dasatinib treatment in a selected subset of patients using YES1 status as predictive biomarker for therapy.

28 May 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
MIMarta Irigoyen
Marta Irigoyen
MPMaría J Pajares
María J Pajares
JAJackeline Agorreta
Jackeline Agorreta
MPMariano Ponz-Sarvisé
Mariano Ponz-Sarvisé
ESElisabeth Salvo
Elisabeth Salvo
ARAna Rouzaut-Subirá
Ana Rouzaut-Subirá
Background: Lung cancer is one of the most prevalent neoplasias in developed countries. Advances in patient survival have been limited and the identification of prognostic molecules is needed. Resistance to treatment is strongly related to tumor cell adhesion to the extracellular matrix and alterations in the quantity and nature of molecules constituting the tumor cell niche. Recently, transforming growth factor beta-induced protein (TGFBI), an extracellular matrix adaptor protein, has been reported to be differentially expressed in transformed tissues. Loss of TGFBI expression has been described in several cancers including lung carcinoma, and it has been suggested to act as a tumor suppressor gene. Results: To address the importance of TGFBI expression in cancer progression, we determined its expression in NSCLC clinical samples using immunohistochemistry. We identified a strong association between elevated TGFBI expression and the response to chemotherapy. Furthermore, we transiently over-expressed and silenced TGFBI in human NSCLC cell lines. Cells over-expressing TGFBI displayed increased sensitivity to etoposide, paclitaxel, cisplatin and gemcitabine. We observed that TGFBI-mediated induction of apoptosis occurred through its binding to αvβ3 integrin. We also determined that full-length TGFBI did not induce caspase 3/7 activation but its proteolytic fragments that were < 3 kDa in size, were able to activate caspase 3, 7 and 8. This pro-apoptotic effect was blocked by anti-αvβ3 integrin antibodies. Conclusions: The results shown here indicate that TGFBI is a predictive factor of the response to chemotherapy, and suggest the use of TGFBI-derived peptides as possible therapeutic adjuvants for the enhancement of responses to chemotherapy.

1 January 2008 in BMC Molecular Biology
Verified
Journal Article
Open access
PDF file
PNPaul Nguewa
Paul Nguewa
JAJackeline Agorreta
Jackeline Agorreta
David BlancoDavid Blanco
David Blanco
Maria D. EscarioMaria D. Escario
Maria D. Escario
JGJavier Gómez-Román
Javier Gómez-Román
ACAlfonso Calvo
Alfonso Calvo
The accurate normalization of differentially expressed genes in lung cancer is essential for the identification of novel therapeutic targets and biomarkers by real time RT-PCR and microarrays. Although classical "housekeeping" genes, such as GAPDH, HPRT1, and beta-actin have been widely used in the past, their accuracy as reference genes for lung tissues has not been proven.

20 June 2018 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
EMElena Martínez‐Terroba
Elena Martínez‐Terroba
CBCarmen Behrens
Carmen Behrens
FMFernando J de Miguel
Fernando J de Miguel
JAJackeline Agorreta
Jackeline Agorreta
EMEduard Monsó
Eduard Monsó
MPMaría J Pajares
María J Pajares